Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Melanoma treatment is being revolutionized by the development of effective immunotherapeutic approaches. These strategies include blockade of immune-inhibitory receptors on activated T cells; for example, using monoclonal antibodies against CTLA-4, PD-1, and PD-L1 (refs 3-5). However, only a subset of patients responds to these treatments, and data suggest that therapeutic benefit is preferentially achieved in patients with a pre-existing T-cell response against their tumour, as evidenced by a baseline CD8(+) T-cell infiltration within the tumour microenvironment. Understanding the molecular mechanisms that underlie the presence or absence of a spontaneous anti-tumour T-cell response in subsets of cases, therefore, should enable the development of therapeutic solutions for patients lacking a T-cell infiltrate. Here we identify a melanoma-cell-intrinsic oncogenic pathway that contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/β-catenin signalling pathway and absence of a T-cell gene expression signature. Using autochthonous mouse melanoma models we identified the mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy. Specific oncogenic signals, therefore, can mediate cancer immune evasion and resistance to immunotherapies, pointing to new candidate targets for immune potentiation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumor-intrinsic activation of the Wnt/β-catenin pathway (15) and deletion or mutation of Pten (16) have been shown to lead to deficient T cell infiltration into the tumor microenvironment and resistance to checkpoint blockade immunotherapy.”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [15]
In the citing paper
“We reveal that the APOE variants exert cell-intrinsic effects on melanoma that impact primary tumor growth and metastatic capacity in a BrafV600E-driven GEMM, a model that has provided numerous important insights into melanoma biology (12,38–40).”
From Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis (2023) · cites this paper as [12]
In the citing paper
“Combinatorial biomarker strategies that capture attributes of the host and tumor-immune ecosystem will be essential (Fig. 2; refs.121-124).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“For example, tumor cell-intrinsic WNT/β-catenin activation has been shown to lead to exclusion of T cells within the TME (123, 155, 156).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [123]
In the citing paper
“Mechanistic studies revealed that Wnt-induced decrease in the expression of the chemokine CCL4 hindered the recruitment of CD103+ DCs and T cells to the tumor microenvironment (Spranger et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Spranger et al., 2015
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,669
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 601–700 of 1,015
Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response
Roelands, J. P., Hendrickx, W., Zoppoli, G. M., Mall, R., Saad, M., Halliwill, K. D., Curigliano, G., Rinchai, D., Decock, J. V., Delogu, L. G., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000617 · Cited by 108
“These errors have now been updated in the article. twitter Wouter Hendrickx @wouterRLH”
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Perrier, A., Didelot, A., Laurent‐Puig, P., Blons, H., & Garinet, S. (2020) · Biomolecules · doi:10.3390/biom10071061 · Cited by 111
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Qin, Y., Han, S., Yu, Y., Ding, Q., Ran, M., Yang, M., Liu, Y., Li, Y., Lu, L., Liu, Y., et al. (2024) · Liver International · doi:10.1111/liv.15953 · Cited by 111
Chang, R. B., & Beatty, G. L. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mir0320-475r · Cited by 106
Wong-Rolle, A., Dong, Q., Zhu, Y., Divakar, P., Hor, J. L., Kedei, N., Wong, M., Tillo, D., Conner, E. A., Rajan, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004698 · Cited by 95
Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone
Trotter, T. N., Gibson, J. T., Lama-Sherpa, T. D., Gowda, P. S., Peker, D., & Yang, Y. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.07.012 · Cited by 100
Salerno, E. P., Bedognetti, D., Mauldin, I. S., Deacon, D. H., Shea, S. M., Pinczewski, J., Obeid, J. M., Coukos, G., Wang, E., Gajewski, T. F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1240857 · Cited by 96
“Other studies have identified molecular mediators of T-cell exclusion from human cancers, including EDNRB overexpression in human ovarian cancers(14) and genes in the WNT/ b-catenin pathway in melanoma.(40,41) Here, we provide new evidence that both melanoma and ovarian cancer cells can express genes encoding proteins…”
BackgroundSelf-citationCytotoxic T cells swarm by homotypic chemokine signalling
Niño, J. L. G., Pageon, S. V., Tay, S. S., Colakoglu, F., Kempe, D., Hywood, J. D., Mazalo, J. K., Cremasco, J., Govendir, M., Dagley, L. F., et al. (2020) · eLife · doi:10.7554/elife.56554 · Cited by 107
Sato, Y., Fu, Y., Liu, H., Lee, M. Y., & Shaw, M. H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08974-3 · Cited by 109
“The tumorintrinsic immunosuppression usually involves the activation of various oncogenic pathways, including Wnt–β-catenin [14, 15], mitogen-activated protein kinase (MAPK) [16, 17], Janus kinase (JAK)–signal transducer and activator of transcription 3 (STAT3) [18] and nuclear factor-κB (NF-κB)”
BackgroundInfluentialCucolo, L., Chen, Q., Qiu, J., Yu, Y., Klapholz, M., Budinich, K. A., Zhang, Z., Shao, Y., Brodsky, I. E., Jordan, M. S., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.007 · Cited by 104
PTEN loss correlates with T cell exclusion across human cancers
Lin, Z., Huang, L., Li, S. L., Gu, J., Cui, X., & Zhou, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08114-x · Cited by 106
Sengupta, S., Das, S., Crespo, Â. C., Cornel, A. M., Patel, A. G., Mahadevan, N. R., Campisi, M., Ali, A. K., Sharma, B., Rowe, J. H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00427-5 · Cited by 106
“No statistical method was used to predetermine sample sizes, but our sample sizes were similar to those reported in previous publications 23,60,61 Extended Data Fig.”
BackgroundMethodSelf-citationCurrent modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Lohmueller, J. J., & Finn, O. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.008 · Cited by 101
Yu, B., Ye, X., Du, Q., Zhu, B., & Zhai, Q. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000475941 · Cited by 100
Xie, K., Xu, L., Wu, H., Liao, H., Luo, L., Liao, M., Gong, J., Deng, Y., Yuan, K., Wu, H. M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1404214 · Cited by 106
“reported that constitutively high b-catenin activity could impair the anti-tumor immunity through defecting recruitment of dendritic cells.(41,42) This failed recruitment of dendritic cells was due to defective production of chemokine CCL4 by tumor intrinsic b-catenin activation.”
Backgroundβ-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas
Nsengimana, J., Laye, J., Filia, A., O’Shea, S., Muralidhar, S., Poźniak, J., Droop, A., Chan, M., Walker, C., Parkinson, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95351 · Cited by 96
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer
Borcoman, É., Rochère, P. D. L., Richer, W., Vacher, S., Chemlali, W., Krucker, C., Sirab, N., Radvanyi, F., Allory, Y., Pignot, G., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1581556 · Cited by 97
“Additionally, tumor-intrinsic active WNT/β-catenin signaling pathway has also been described to induce T-cell exclusion from the tumor tissue mediated by decreased production of chemokines.(36) Moreover, a panel of chemokines (CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10) was described to be expressed in metastatic melan…”
BackgroundIntrinsic β-catenin signaling suppresses CD8+ T-cell infiltration in colorectal cancer
Xue, J., Yu, X., Xue, L., Ge, X., Zhao, W., & Peng, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108921 · Cited by 94
Kobayashi, Y., Lim, S., & Yamaguchi, H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.011 · Cited by 100
Song, K., Oh, S. J., Kim, S., Cho, H., Lee, H.-J., Song, J. S., Chung, J., Cho, E., Lee, J., Jeon, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14259-y · Cited by 105
Oncolytic Adenovirus: Prospects for Cancer Immunotherapy
Zhao, Y., Liu, Z., Li, L., Wu, J., Zhang, H., Zhang, H., Lei, T., & Xu, B. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.707290 · Cited by 108
SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
Christofides, A., Katopodi, X.-L., Cao, C., Karagkouni, D., Aliazis, K., Yenyuwadee, S., Aksoylar, H., Pal, R., Mahmoud, M. A. A., Strauss, L., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01385-x · Cited by 99
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors
Kakavand, H., Rawson, R. V., Pupo, G. M., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., Kefford, R. F., Howle, J. R., Saw, R. P. M., Thompson, J. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1688 · Cited by 91
Luo, F., Lu, F.-T., Cao, J.-X., Ma, W.-J., Xia, Z.-F., Zhan, J.-H., Zeng, K.-M., Huang, Y., Zhao, H.-Y., & Zhang, L. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.027 · Cited by 95
The Cancer Immunotherapy Biomarker Testing Landscape
Walk, E. E., Yohe, S. L., Beckman, A., Schade, A. E., Zutter, M. M., Pfeifer, J. D., & Berry, A. B. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0584-cp · Cited by 107
The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer
Ferguson, L. P., Diaz, E., & Reya, T. (2021) · Trends in cancer · doi:10.1016/j.trecan.2020.12.014 · Cited by 102
“For example, tumor-intrinsic upregulation of Wnt/βcatenin in melanoma has been associated with reduced T cell infiltration and poor clinical response to immunotherapy [34].”
BackgroundHo, W. W., Gomes-Santos, I. L., Aoki, S., Datta, M., Kawaguchi, K., Talele, N. P., Roberge, S., Ren, J. P., Liu, H., Chen, I. X., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105323118 · Cited by 102
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma
Brennan, K., Shin, J. H., Tay, J. K., Prunello, M., Gentles, A. J., Sunwoo, J. B., & Gevaert, O. (2017) · Scientific Reports · doi:10.1038/s41598-017-17298-x · Cited by 95
New pathways in immune stimulation: targeting OX40
Silva, C. A. C., Facchinetti, F., Routy, B., & Derosa, L. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000573 · Cited by 97
Onuma, A. E., Zhang, H., Huang, H., Williams, T. M., Noonan, A. M., & Tsung, A. (2020) · Gene Expression · doi:10.3727/105221620x15880179864121 · Cited by 99
Debebe, A., Medina, V, Chen, C.-Y., Mahajan, I. M., Jia, C., Fu, D., He, L., Zeng, N., Stiles, B. W., Chen, C.-L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.207 · Cited by 89
New Strategies in Bladder Cancer: A Second Coming for Immunotherapy
Ghasemzadeh, A., Bivalacqua, T. J., Hahn, N. M., & Drake, C. G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1135 · Cited by 103
Frizzled7: A Promising Achilles’ Heel for Targeting the Wnt Receptor Complex to Treat Cancer
Phesse, T. J., Flanagan, D. J., & Vincan, E. (2016) · Cancers · doi:10.3390/cancers8050050 · Cited by 98
“Conversely, it has been shown that cell intrinsic canonical Wnt signalling mediates resistance to recent immunotherapy approaches such as PD-1 inhibitors [207], thus suggesting that activation of Wnt would not be an effective therapy, at least not in combination with the promising immune check point inhibitors.”
BackgroundKumar, S., Calianese, D., & Birge, R. B. (2017) · Immunological Reviews · doi:10.1111/imr.12587 · Cited by 93
Walsh, R. J., & Soo, R. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937902 · Cited by 100
Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade
Nair, S., Mazzoccoli, L., Jash, A., Govero, J., Bais, S. S., Hu, T., Fontes-Garfias, C. R., Shan, C., Okada, H., Shresta, S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.144619 · Cited by 96
Wu, S.-Y., Xiao, Y., Wei, J., Xu, X., Jin, X., Hu, X., Li, D., Jiang, Y., & Shao, Z.-M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002528 · Cited by 100
Association between immune-related adverse event timing and treatment outcomes
Hsiehchen, D., Naqash, A. R., Espinoza, M., von Itzstein, M. S., Cortellini, A., Ricciuti, B., Owen, D. H., Laharwal, M., Toi, Y., Burke, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.2017162 · Cited by 99
Current Uses of Mushrooms in Cancer Treatment and Their Anticancer Mechanisms
Park, H.-J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810502 · Cited by 94
“An inverse correlation has been reported between β-catenin/Wnt activation in cancer and the degree of CD8+ T cell infiltration in a mouse model of melanoma [60].”
BackgroundYeh, C. Y., Aguirre, K., Laveroni, O., Kim, S., Wang, A., Liang, B., Zhang, X., Han, L. M., Valbuena, R., Bassik, M. C., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01943-5 · Cited by 103
Mechanisms of Intrinsic Tumor Resistance to Immunotherapy
Rieth, J. M., & Subramanian, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051340 · Cited by 95
“They attributed the mechanism of inhibited dendritic cell infiltration to, in part, a reduction in the production of the chemokine CCL4 by Wnt–β-catenin activation [54].”
BackgroundChen, H., Xu, L., Li, L., Liu, X., Gao, J., & Bai, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-30417-6 · Cited by 99
Lei, M., Siemers, N. O., Pandya, D., Chang, H., Sánchez, T., Harbison, C. T., Szabó, P. M., Janjigian, Y. Y., Ott, P. A., Sharma, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2790 · Cited by 97
DeVito, N. C., Sturdivant, M. S., Thievanthiran, B., Xiao, C., Plebanek, M. P., Salama, A. K. S., Beasley, G. M., Holtzhausen, A., Novotny‐Diermayr, V., Strickler, J. H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109071 · Cited by 93
“…an association between Wnt-β -catenin activation and T cell exclusion; however, only ~15% of T cell-poor tumors harbor genetic mutations or copy number variations impacting downstream mediators that drive the activation of the β -catenin signaling pathway (Luke et al., 2019; Spranger et al., 2015).”
InfluentialQuek, C. Y. J., Pratapa, A., Bai, X., Al‐Eryani, G., da Silva, I. P., Mayer, A. T., Bartoniček, N., Harvey, K., Maher, N. G., Conway, J. W., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114392 · Cited by 107
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
McKenzie, J. A., Mbofung, R. M., Malu, S., Zhang, M., Ashkin, E., Devi, S., Williams, L., Tieu, T., Peng, W., Pradeep, S., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx257 · Cited by 91
“Others have shown that activation of Wnt/b-catenin is associated with a non-T-cell-inflamed state in melanoma and is correlated with resistance to immune checkpoint blockade (11).”
BackgroundCTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients
Goltz, D., Gevensleben, H., Vogt, T. J., Dietrich, J., Golletz, C., Bootz, F., Kristiansen, G., Landsberg, J., & Dietrich, D. (2018) · JCI Insight · doi:10.1172/jci.insight.96793 · Cited by 96
“Tumor cell–intrinsic activation of β-catenin signaling can induce CTLA-4 expression and has been associated with a non–T cell–inflamed microenvironment and resistance to ICB (24).”
BackgroundSánchez-Paulete, A. R., Teijeira, Á., Quetglas, J. I., Rodriguez-Ruiz, M. E., Sánchez-Arráez, Á., Labiano, S., Etxeberría, I., Azpilikueta, A., Bolaños, E., Ballesteros-Briones, M. C., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0933 · Cited by 94
“Further enhancement of cDC1 content in the tumor microenvironment warrants future research, for instance using other chemokines known to attract thisDC subset, such asCCL4 (50).”
MethodToward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R., Palucka, K., Samayoa, J., Spranger, S., Warren, S., Wong, K.-K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0602-4 · Cited by 88
Self-citationDistinct Colorectal Cancer–Associated APC Mutations Dictate Response to Tankyrase Inhibition
Schatoff, E. M., Goswami, S., Zafra, M. P., Foronda, M., Shusterman, M., Leach, B. I., Katti, A., Diaz, B. J., & Dow, L. E. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0289 · Cited by 89
Morita, M., Nishida, N., Sakai, K., Aoki, T., Chishina, H., Takita, M., Ida, H., Hagiwara, S., Minami, Y., Ueshima, K., et al. (2021) · Liver Cancer · doi:10.1159/000516899 · Cited by 97
Molecular patterns of resistance to immune checkpoint blockade in melanoma
Lauss, M., Phung, B., Borch, T. H., Harbst, K., Kaminska, K. K., Ebbesson, A., Hedenfalk, I. A., Yuan, J., Nielsen, K., Ingvar, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47425-y · Cited by 96
“Tumor-cell intrinsic factors include tumor mutational burden 8-10 , mutational subsets 11 , clonality 12 , aneuploidy 13 , immune evasion 14,15 , MHC antigen presentation 16,17 and interferon gamma signaling 10,18,19 .”
BackgroundTwelve-year survival and immune correlates in dendritic cell–vaccinated melanoma patients
Gross, S., Erdmann, M., Haendle, I., Voland, S., Berger, T., Schultz, E., Strasser, E., Dankerl, P., Janka, R., Schliep, S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91438 · Cited by 87
“ses, indicating that our patient population was not enriched for an immunologically highly favorable subset, considering that overall 40% of melanoma metastases are reported to be T cell–rich in large data sets (45, 49).”
BackgroundThe Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 98
Abd Hamid, M., Wang, R.-Z., Yao, X., Fan, P., Li, X., Chang, X.-M., Feng, Y., Jones, S., Maldonado-Perez, D., Waugh, C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0885 · Cited by 86
“However, other murine studies have also shown that tumor APCs can be dysregulated to become tolerogenic, a process driven by immunosuppressive factors such as IL10 and β-catenin (26, 27, 34, 35).”
BackgroundPore, N., Wu, S., Standifer, N., Jure-Kunkel, M., de los Reyes, M., Shrestha, Y., Halpin, R., Rothstein, R., Mulgrew, K., Blackmore, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1543 · Cited by 88
Adapting Cancer Immunotherapy Models for the Real World
Klevorn, L. E., & Teague, R. M. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.03.010 · Cited by 88
“treatment of melanoma depends in part on established T cell infiltration into tumors, which is disrupted by tumor-intrinsic WNT/b-catenin signaling [80].”
BackgroundThe Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer
Nair, S. S., Weil, R., Dovey, Z. S., Davis, A., & Tewari, A. K. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.10.005 · Cited by 98
The diversity of CD8+ T cell dysfunction in cancer and viral infection
Galluzzi, L., Smith, K. N., Liston, A., & Garg, A. D. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01161-6 · Cited by 106
The role of dendritic cells in cancer
Hansen, M., & Andersen, M. H. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0592-y · Cited by 95
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy
Spranger, S., Sivan, A., Corrales, L., & Gajewski, T. F. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.003 · Cited by 85
Self-citationCellular determinants and therapeutic implications of inflammation in pancreatic cancer
Stone, M. L., & Beatty, G. L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.012 · Cited by 90
Danieau, G., Morice, S., Rédiní, F., Verrecchia, F., & Royer, B. B.-L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153751 · Cited by 93
“Moreover, the active Wnt / β -catenin signaling pathway has been associated with T cell exclusion leading to resistance to anti-PDL-1 therapy in human melanoma [176] (Figure 2e).”
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Rizzo, A., Cusmai, A., Gadaleta‐Caldarola, G., & Palmiotti, G. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2064273 · Cited by 87
“observing resistance to ICIs in mouse models with malignancies harboring β-catenin aberrations [70,71].”
BackgroundImmune-checkpoint blockade — durable cancer control
Buchbinder, E. I., & Hodi, F. S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.237 · Cited by 87
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Davar, D., Wang, H., Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Ka, M., Menna, C., Rose, A., Sander, C., Borhani, A. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00632 · Cited by 86
Patient‑derived xenograft mouse models: A high fidelity tool for individualized medicine (Review)
Xu, C., Li, X., Liu, P., Li, M., & Luo, F. (2018) · Oncology Letters · doi:10.3892/ol.2018.9583 · Cited by 112
“In traditional cell lines, established cells are cultured in artificial conditions that may not accurately simulate complex biological conditions, including tumor progression in low oxygen conditions (4), excessive hypoxia-induced transcription factor activation (5), immune escape mechanism deficiency (6) and angiogen…”
BackgroundWang, H., Li, S., Wang, Q., Jin, Z., Shao, W., Gao, Y., Li, L., Lin, K., Zhu, L., Wang, H., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd7851 · Cited by 93
“Next, the predicted hot or cold tumors were pairwise compared to the actual hot or cold tumors (23); the prediction accuracy and ROC (receiver operating characteristic) curve could be obtained according to the comparison results.”
BackgroundMethodResultInfluentialRedín, E., Garmendia, I., Lozano, T., Serrano, D., Senent, Y., Redrado, M., Villalba-Esparza, M., de Andrea, C. E., Expósito, F., Ajona, D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001496 · Cited by 90
“32 Similarly, gain in Myc function inhibits CD4+ T-cell activation and infiltration.”
BackgroundWnt signaling in cancer: from biomarkers to targeted therapies and clinical translation
Tufail, M., Jiang, C., & Li, N. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02306-w · Cited by 91
“High β-catenin activity disrupts the recruitment of CD103 + dendritic cells, which are essential for T-cell priming against tumor antigens [346].”
Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment
Comen, E. A., Bowman, R. L., & Kleppe, M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00056 · Cited by 99
Sferrazza, G., Corti, M., Brusotti, G., Pierimarchi, P., Temporini, C., Serafino, A., & Calleri, E. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.019 · Cited by 98
New Opportunities and Challenges to Defeat Cancer Stem Cells
Ramos, E. K., Hoffmann, A. D., Gerson, S. L., & Liu, H. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.08.007 · Cited by 89
“CSCs have numerous properties that allow them to persist through chemotherapy, radiation, and other treatments [2,24,28,53,58,59,127].”
BackgroundAnagnostou, V., Bruhm, D. C., Niknafs, N., White, J. R., Shao, X. M., Sidhom, J.-W., Stein, J. E., Tsai, H., Wang, H., Belcaid, Z., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100139 · Cited by 88
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
Yuan, Y. J., Adam, A., Zhao, C., & Chen, H. (2021) · Cancers · doi:10.3390/cancers13040663 · Cited by 92
“An activated Wnt/β-catenin pathway is correlated to loss of T-cell gene expression in metastatic melanoma [96].”
BackgroundFujita, M., Yamaguchi, R., Hasegawa, T., Shimada, S., Arihiro, K., Hayashi, S., Maejima, K., Nakano, K., Fujimoto, A., Ono, A., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102659 · Cited by 87
“This association was initially reported in melanoma [29], but similar trends have been observed in multiple cohorts of HCC [9,11,30].”
ResultITGA5 is a prognostic biomarker and correlated with immune infiltration in gastrointestinal tumors
Zhu, H. H., Wang, G., Zhu, H., & Xu, A. (2021) · BMC Cancer · doi:10.1186/s12885-021-07996-1 · Cited by 92
Immune Therapy Resistance and Immune Escape of Tumors
Seliger, B., & Massa, C. (2021) · Cancers · doi:10.3390/cancers13030551 · Cited by 86
“As a consequence of hyperactive β-catenin signaling in murine models, tumor cells do not express chemokines such as CCL4 [24] or CCL5 [25], resulting in a reduced or missing recruitment of Batf3-dependent DCs that are required for priming antigen-specific CD8+ T cells [24].”
BackgroundTranscriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Ascierto, M. L., Makohon-Moore, A. P., Lipson, E. J., Taube, J. M., McMiller, T. L., Berger, A. E., Fan, J., Kaunitz, G. J., Cottrell, T. R., Kohutek, Z. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0270 · Cited by 86
Kallert, S. M., Darbre, S., Bonilla, W. V., Kreutzfeldt, M., Page, N., Müller, P., Kreuzaler, M., Lu, M., Favre, S., Kreppel, F., et al. (2017) · Nature Communications · doi:10.1038/ncomms15327 · Cited by 88
Liu, Q., Zhu, H., Tiruthani, K., Shen, L., Chen, F., Gao, K., Zhang, X., Hou, L., Wang, D., Liu, R., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07384 · Cited by 85
Tumor-Derived Lactic Acid Contributes to the Paucity of Intratumoral ILC2s
Wagner, M., Ealey, K. N., Tetsu, H., Kiniwa, T., Motomura, Y., Moro, K., & Koyasu, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.103 · Cited by 86
Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors
Donnadieu, E., Dupré, L., Pinho, L. G., & Cotta-de-Almeida, V. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.1mr0520-746r · Cited by 87
Systematic characterization of mutations altering protein degradation in human cancers
Tokheim, C., Wang, X., Timms, R. T., Zhang, B., Mena, E. L., Wang, B., Chen, C., Ge, J., Chu, J., Zhang, W., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.020 · Cited by 83
Matas-Rico, E., Frijlink, E., Àvila, I. V. D. H., Menegakis, A., van Zon, M., Morris, A. J., Köster, J., Salgado-Polo, F., de Kivit, S., Lança, T., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110013 · Cited by 91
“Tumor-intrinsic mechanisms underlying T cell exclusion involve, for example, transcriptional chemokine silencing (Spranger et al., 2015; Spranger and Gajewski, 2018) and production of immunosuppressive cytokines such as transforming growth factor β (TGF-β ) (Batlle and Massagué, 2019; Mariathasan…”
Chen, X., Feng, L., Huang, Y., Wu, Y., & Xie, N. (2022) · Cancers · doi:10.3390/cancers15010104 · Cited by 94
“Tumors with high β-catenin expression have low numbers of CD103+ DCs in the TME, resulting in impaired antigen delivery and presentation, which in turn affects T cell infiltration and immune response in the microenvironment [119].”
BackgroundLifting the innate immune barriers to antitumor immunity
Rothlin, C. V., & Ghosh, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000695 · Cited by 88
“…of the stimulator of interferon genes (STING) pathway, 21 type I interferons (IFNs), 22 signatures of wound healing and obesity, 23 24 while negative correlates include unfavorable gut microbiome, 25 Wnt/ β -catenin signaling 17 and stromal factors in the tumor microenvironment such as TGF β .”
FOXOs in cancer immunity: Knowns and unknowns
Deng, Y., Wang, F., Hughes, T. L., & Yu, J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.005 · Cited by 90
He, W., Wang, S., Yan, J., Qu, Y., Jin, L., Sui, F., Li, Y., You, W., Yang, G., Yang, Q., et al. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201807736 · Cited by 82
Siolas, D., Vucic, E., Kurz, E., Hajdu, C., & Bar-Sagi, D. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109578 · Cited by 80
“…A uthor M anuscript Different tumor genetic backgrounds can profoundly influence the composition of the immune microenvironment, as demonstrated in melanoma, breast, and prostate cancers, through distinct cellular mechanisms (Bezzi et al., 2018; Spranger et al., 2015; Wellenstein et al., 2019).”
BackgroundWu, W., Liu, Y., Zeng, S., Han, Y., & Shen, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01166-3 · Cited by 88
Photoactivatable Silencing Extracellular Vesicle (PASEV) Sensitizes Cancer Immunotherapy
Lu, M., Xing, H., Shao, W., Zhang, T., Zhang, M., Wang, Y., Li, F., Weng, Y., Zheng, A., Huang, Y., et al. (2022) · Advanced Materials · doi:10.1002/adma.202204765 · Cited by 84
Wang, D., Cui, Q., Yang, Y. J., Liu, A. Q., Zhang, G., & Yu, J. C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113541 · Cited by 94
Melero, I., Tanos, T., Bustamante, M., Sanmamed, M. F., Calvo, E., Moreno, I., Moreno, V., Hernández‐Guerrero, T., Martinez‐García, M., Rodríguez‐Vida, A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abp9229 · Cited by 91
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy
Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 87
The origin of DCs and capacity for immunologic tolerance in central and peripheral tissues
Devi, K. S. P., & Anandasabapathy, N. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0602-0 · Cited by 92
“contexts, Flt3L treatment of DCs also contributes to entry of T cells into tumors [90, 91] but close attention must be paid to contexts in which TLR adjuvant was given to mature DC.”
Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
van Gulijk, M., Dammeijer, F. F., Aerts, J. G. J. V., & Vroman, H. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02759 · Cited by 86
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 83
“In addition, Wnt/β-catenin signaling could directly inhibit T cell activation [76].”
BackgroundIndicators of responsiveness to immune checkpoint inhibitors
Shields, B. D., Mahmoud, F. A., Taylor, E. M., Byrum, S. D., Sengupta, D., Koss, B. S., Baldini, G., Ransom, S. C., Cline, K., Mackintosh, S. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01000-2 · Cited by 81
Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer
Zhao, J., Xiao, Z., Li, T., Chen, H., Yuan, Y., Wang, Y., Hsiao, C.-H., Chow, D. S., Overwijk, W. W., & Li, C. (2018) · ACS Nano · doi:10.1021/acsnano.8b02481 · Cited by 84
Metadata
- Authors
- Spranger, S., Bao, R., & Gajewski, T. F.
- Affiliations
- University of Chicago (US)
- Corresponding author
- Gajewski, Thomas F.
- Venue
- Nature
- Published
- 2015-05-11
- Volume
- 523
- Issue
- 7559
- Pages
- 231-235
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1498931318
- Cited by
- 2,830
- References
- 45
- Citations by year
- 2026: 240 · 2025: 234 · 2024: 222 · 2023: 270 · 2022: 319 · 2021: 367 · 2020: 337 · 2019: 246 · 2018: 198 · 2017: 212 · 2016: 151 · 2015: 31
- FWCI
- 86.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- melanoma, β-catenin signaling, Wnt signaling, cancer immunotherapy resistance, PD-L1 blockade, CTLA-4 blockade, T-cell exclusion, tumor microenvironment, CD8+ T cell infiltration, tumor immune evasion, oncogenic signaling, immune checkpoint blockade
- MeSH terms
- Animals, Humans, Immunotherapy, Melanoma, T-Lymphocytes, Signal Transduction, Gene Expression Regulation, Neoplastic, Gene Expression Profiling, Wnt Proteins, beta Catenin, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.